{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027406","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.424130+00:00","generated_at":"2026-06-12T06:00:05.883670+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Twist Bioscience reports Q3 FY2023 revenue of $63.7M (up 14% YoY); CFO to transition to new role","bullets":["Revenue $63.7M, up 14% YoY from $56.1M; net loss $57.4M ($1.01/share) vs $60.5M prior year.","CFO James Thorburn will transition to a new commercial/scaling role once successor is hired; search underway.","Cash and investments $357.1M at June 30, 2023; shipped products to ~2,200 customers.","Launched RNA sequencing portfolio; entered collaboration with Cancer Research Horizons."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027406","json":"https://secwatch.observer/filing/0001628280-23-027406.json","markdown":"https://secwatch.observer/filing/0001628280-23-027406.md","text":"https://secwatch.observer/filing/0001628280-23-027406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/0001628280-23-027406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/twist-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T06:00:05.883670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a82de68ba5e412e10d30f54253233225e102cc37","claim":"Twist Bioscience Corp reported the third quarter of fiscal 2023 ended June 30, 2023 results: revenue $63.7 million.","evidence_excerpt":"Century Archive workflow by the end of calendar 2023. \" FISCAL 2023 THIRD QUARTER FINANCIAL RESULTS • Orders: Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 million for the same period of fiscal 2022 . • Revenue: Total revenues for the third quarter of fiscal 2023 were $63.7 million compared to $56.1 million for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/0001628280-23-027406-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of fiscal 2023 ended June 30, 2023"},{"label":"Revenue","value":"$63.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a806620ba3","claim":"James Thorburn changed role as Chief Financial Officer at Twist Bioscience Corp.","evidence_excerpt":"On August 3, 2023, the Company and James Thorburn, the Company's Chief Financial Officer, mutually agreed that Mr. Thorburn will transition to a new role responsible for guiding the Company’s commercial scaling, operational leverage and DNA data storage business, once a new Chief Financial Officer is appointed.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/0001628280-23-027406-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transition to a new role"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}